BREAKING NEWS

Durvalumab/tremelimumab combo fails to improve PFS compared to chemotherapy
Eisai is first to take advantage of new FDA regulatory pathway
Violations focused on promotion of Thalomid and Revlimid
U.S. poses challenges for biosimilars, consultant argues
9-year-old treated for 40 weeks in infancy is the third such reported case
Researchers suggest FDA regulation of yohimbe and energy products
Patients who discontinue statins increase their risk for death, heart attack, or stroke
A 5% drop would cause annual measles cases to triple, according to study
Declining cases of infection and limitations of the blood test prompt revision
Renflexis also costs 20% less than a biosimilar already on the market

P&T TV

SIRT for Liver Cancer: Similar Efficacy, Less Toxicity Than Sorafenib

Valérie Vilgrain, MD, of Hôpital Beaujon Service de Radiologie in Paris, describes results of the SARAH trial. Selective internal radiation therapy provided efficacy similar to sorafenib for hepatocellular carcinoma but with considerably fewer adverse events.

European Association for the Study of the Liver International Liver Congress, April 2017

P&T July 2017
Table of Contents

Features

Raising their voices in nearly unanimous opposition, pharmaceutical manufacturers and their suppliers have mounted a campaign to dissuade the FDA from launching a voluntary program in 2018 that is aimed at reducing drug shortages.
This article, the second in a series of three, provides an overview of the efficacy and safety of cancer immunotherapies ranging from monoclonal antibodies to vaccines, including additional clinical considerations regarding immune checkpoint blockers.
A recent guideline update for the treatment of heart failure has created the need for a new look at the medication classes and trials related to the disease. The authors focus on pharmacological options available for treating the problem.
Pharmacovigilance Forum
Torsades de pointes (TdP)—an uncommon but life-threatening polymorphic ventricular tachycardia—is almost always drug induced. The authors describe the causes, risk factors, symptoms, diagnosis, and treatment of TdP.
Meeting Highlights
At an event focusing on population-health approaches to the opioid epidemic, discussants agreed that better coordination of care, community involvement in finding solutions, and more consistent use of improved pain-control options are required.

Departments

Medication Errors
Strengthen your resolve: no unlabeled containers anywhere, ever!
Prescription: Washington
A significant change in tiering exceptions policy for Part D is coming in 2018
Approvals, new indications, regulatory activities, and more
Niraparib (Zejula) for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; ocrelizumab (Ocrevus) for relapsing or primary progressive multiple sclerosis; and dupilumab (Dupixent) for moderate-to-severe atopic dermatitis
Drug Forecast
Eluxadoline (Viberzi) for the treatment of irritable bowel syndrome with diarrhea